Company Overview and News

2
Stocks rise as earning expectations beat China growth fears

2018-07-16 thehindubusinessline
European shares mostly opened higher, although the gains were marginal. Germany's DAX was the biggest riser, up half a per cent before giving up most of those gains.
ICICIBANK 500116 AUROPHARMA 524804 532174 IBN ARBQY IDBI MSCI

0
Sugar stocks turn sour

2018-07-16 thehindubusinessline
Shares of sugar producers fell in the afternoon trade on a report that the government may increase the fair and remunerative price (FRP) for sugarcane by Rs 20 to Rs 275 per quintal.
ICICIBANK 500116 AUROPHARMA 524804 532174 IBN ARBQY IDBI 500119 DHAMPURSUG

0
Metal cos likely to report strong earnings in June quarter

2018-07-16 thehindubusinessline
Steel Authority of India is expected to show Q/Q EBITDA growth of 2 per cent, while volumes are seen falling 12 per cent Q/Q, and input costs rising due to higher coking coal costs.
HINDALCO 500116 AUROPHARMA 524804 IBN IDBI HNDNF ICICIBANK 500470 TTST TATASTEEL TATLY 532174 ARBQY 500440

0
India's June palm oil imports plunge to 4-1/2 yr low

2018-07-16 thehindubusinessline
India's palm oil imports in June plunged 41 percent from a year earlier to their lowest in nearly 4-1/2 years, a leading trade body said on Monday, as a higher import tax on the tropical oil made it more expensive.
ICICIBANK 500116 AUROPHARMA 524804 532174 IBN ARBQY IDBI

0
LIC board approves IDBI Bank buyout; lender shares slump 7%

2018-07-16 thehindubusinessline
Shares of IDBI Bank plunged as much as 7 per cent to Rs 53.30 after the LIC board approved acquisition of up to 51 per cent stake in IDBI Bank. Now, the state-owned Life Insurance Corporation will approach the Securities and Exchange Board of India for its approval.
ICICIBANK 500116 AUROPHARMA 524804 532174 IBN ARBQY IDBI

0
ICICI Bank hits 9-month low

2018-07-16 thehindubusinessline
Shares of ICICI Bank Ltd fell as much as 4.2 per cent to Rs 256.5, lowest since October 24, 2017.
ICICIBANK AUROPHARMA 524804 532174 IBN ARBQY

0
Aurobindo falls 4% despite acquisition of European firm Apotex, Credit Suisse sees 16% upside

2018-07-16 moneycontrol
Aurobindo Pharma share price declined 4.4 percent intraday Monday despite the company acquired Europe-based firm Apotex for 74 million euro.
AUROPHARMA 524804 ARBQY

0
HUL hits record high ahead of quarterly results

2018-07-16 thehindubusinessline
India's fourth-largest listed company by market cap is set to report a record quarterly profit of Rs 1,530 crore for the June quarter on Monday, a 19.3 per cent jump on year.
AUROPHARMA 524804 ARBQY 500696 HINDUNILVR

0
Glenmark falls 2.4% as CCI slaps Rs 47 cr penalty

2018-07-16 thehindubusinessline
Shares of Glenmark Pharmaceuticals fell as much as 2.4 per cent to Rs 551.50, their lowest since June 8, on CCI penalty.
GLENMARK 532296 AUROPHARMA 524804 ARBQY GLKQY

0
Infosys shares jump over 5%; brokerages upbeat on growth prospects

2018-07-16 thehindubusinessline
Shares of India's No.2 software services exporter, Infosys Ltd, jumped as much as 5.1 per cent to Rs 1,384.40, and the brokerages are upbeat on the company’s growth prospects.
MS.PRI AUROPHARMA MS.PRK 524804 ARBQY MS.PRE INFY MS.PRF MS.PRG MS MS.PRA

0
Aurobindo Pharma drops 2.3%

2018-07-16 thehindubusinessline
Shares of Aurobindo Pharma dropped as much as 2.26 per cent to Rs 589.30 on the BSE.
AUROPHARMA 524804 ARBQY

0
Multiplex operators’ shares tank to 10-month low

2018-07-16 thehindubusinessline
Shares of Indian cinema theatre operators extended decline to a near 10-month low. PVR Ltd and INOX Leisure Ltd slumped as much as 3.6 per cent and 9.2 per cent, respectively.
AUROPHARMA 524804 ARBQY 532706 INOXLEISUR

0
Aurobindo Pharma Limited - Press Release

2018-07-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
AUROPHARMA 524804 ARBQY

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...